CompletedNCT02422186
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Medication studyAges 65+Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who was this study for?
Listed age limits: from 65 years.
- Listed locations
- San Diego and 68 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 20, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 139
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- Over 65 Years
- Official registry ID
- NCT02422186
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression
Get this study by email
Recruitment & locations
CompletedSan Diego, United States · New Haven, United States · Miami, United States
66 more locations
- Marietta, United States
- Iowa City, United States
- Baltimore, United States
- Watertown, United States
- New York, United States
- Staten Island, United States
- Cincinnati, United States
- Allentown, United States
- Dallas, United States
- Wichita Falls, United States
- Charlottesville, United States
- Richland, United States
- Aalst, Belgium
- Bruges, Belgium
- Brussels, Belgium
- Hasselt, Belgium
- Heusden-Zolder, Belgium
- Liège, Belgium
- Belo Horizonte, Brazil
- Fortaleza, Brazil
- Rio de Janeiro, Brazil
- Santo André, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Helsinki, Finland
- Kuopio, Finland
- Issy-les-Moulineaux, France
- La Tronche, France
- Nice, France
- Nîmes, France
- Paris, France
- Poitiers, France
- Toulon, France
- Toulouse, France
- Tours, France
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Bełchatów, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Torun, Poland
- Tuszyn, Poland
- Cape Town, South Africa
- Garsfontein, South Africa
- Pretoria, South Africa
- Badajoz, Spain
- Bilbao, Spain
- Madrid, Spain
- Ourense, Spain
- Sant Boi de Llobregat, Spain
- Torrevieja, Spain
- Zamora, Spain
- Gothenburg, Sweden
- Halmstad, Sweden
- Lund, Sweden
- Skövde, Sweden
- Solna, Sweden
- Stockholm, Sweden
- Derbyshire, United Kingdom
- Oxford, United Kingdom
- Preston, United Kingdom
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant) and Venlafaxine Extended Release (XR) (New Antidepressant).
Who was this study for?
Listed age limits: from 65 years.
